However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...
Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers ...
Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...
The orally-available MDM2-p53 agonist is designed to restore the function of p53, the most frequently mutated gene in cancer, which has so far resisted drug development efforts. The p53 gene ...
INR:0411. hardik pandya age Hebo Pharmaceuticals passed the hearing of the Hong Kong Stock Exchange and 4 innovative drug candidates have entered the clinical s ...
It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor ...